BiotechTube

Liposomal Annamycin

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Leukemia, Myeloid, Acute

Conditions

Leukemia, Myeloid, Acute

Trial Timeline

Mar 28, 2018 → Jun 20, 2020

NCT ID
NCT03315039

About Liposomal Annamycin

Liposomal Annamycin is a phase 1/2 stage product being developed by Moleculin Biotech for Leukemia, Myeloid, Acute. The current trial status is completed. This product is registered under clinical trial identifier NCT03315039. Target conditions include Leukemia, Myeloid, Acute.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (2)

NCT IDPhaseStatus
NCT03388749Phase 1/2Completed
NCT03315039Phase 1/2Completed

Competing Products

20 competing products in Leukemia, Myeloid, Acute

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
25
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
51
TERN-701Terns PharmaceuticalsPhase 1/2
38
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
28
PRGN-3006 T CellsPrecigenPhase 1
28
BisantreneRace OncologyPhase 2
44
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
25
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
44
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
33
ZN-d5Zentalis PharmaceuticalsPhase 1
25
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
77
PirtobrutinibEli LillyPhase 2
52
Ibrutinib + LY3214996Eli LillyPhase 1
33
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
52
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
25
Pirtobrutinib + IbrutinibEli LillyPhase 3
77
LY2523355Eli LillyPhase 1
33
TomivosertibeFFECTOR TherapeuticsPhase 1
25
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
77

Other Products from Moleculin Biotech

Placebo in combination with Cytarabine Injection + Liposomal Annamycin Injection in combination with Cytarabine Injection + Liposomal Annamycin Injection in combination with Cytarabine Injection + Liposomal Annamycin for Injection in combination with Cytarabine Injection.Phase 2/3
57
STAT3 Inhibitor WP1066Phase 2
44
Liposomal Annamycin + CytarabinePhase 1/2
33
Liposomal Annamycin (L-Annamycin)Phase 1/2
33
Liposomal AnnamycinPhase 1/2
33